文献速递类风湿关节炎脊柱关节炎

类风湿关节炎与脊柱关节炎患者对改善病情抗风湿药的态度与体验:定性综合

Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-03-24

该定性综合纳入56项研究、1383例成人患者(RA 1149例,SpA 191例,未指定43例),检索至2016年1月,采用主题综合法分析。识别出6个主题,包括疾病身份强化、令人痛苦的 uncertainties 与后果、强大的社会影响、生物制剂获取特权与权利、维持控制及协商治疗期望。患者视DMARDs为有惊人副作用的强效药物,信任医疗、他人正面体验及维持生活参与的期望可促使用药。

要点

  • 患者视DMARDs为强效药物且副作用令人担忧,会强化疾病身份感。
  • 对医疗的信任、其他患者的正面体验及维持生活参与的期望可促使用药。
  • 创造支持性环境让患者表达担忧可能改善治疗满意度、依从性与健康结局。

核心结论

  • 患者认为DMARDs是伴有令人警觉副作用的强效药物,并会强化其疾病身份。
  • 对医疗的信任与信心、其他患者使用DMARDs的正面体验以及药物有助于维持生活参与的期望,可激励患者使用DMARDs。
  • 为患者创造支持性环境以表达其担忧,可能改善治疗满意度、依从性和健康结局。

研究设计与样本

  • 定性综合研究,检索MEDLINE、Embase、PsycINFO和CINAHL数据库至2016年1月。
  • 采用主题综合法分析纳入研究的结果。
  • 共纳入56项研究,涉及1383例成人患者(RA 1149例,SpA 191例,未指定43例)。

主要发现

  • 识别出6个主题(含亚主题):疾病身份强化、令人痛苦的 uncertainties 与后果、强大的社会影响、生物制剂获取特权与权利、维持控制、协商治疗期望。
  • 疾病身份强化包括突然药物治疗的严重性、预示健康恶化和令人生畏的终身治疗。
  • 令人痛苦的 uncertainties 与后果包括毒害身体、怀疑疗效、矛盾混乱的建议和改变治疗方案带来的预后不确定性。
  • 强大的社会影响包括受他人经历影响、与医生合作、维持角色、对全面持续照护的信心和重视同伴支持。
  • 生物制剂获取特权与权利包括昂贵药物必须更好、有权获得生物制剂和害怕被剥夺。

临床怎么用

  • 临床应关注患者对DMARDs副作用的担忧及其对疾病身份的影响。
  • 通过建立信任、提供其他患者正面用药体验信息及强调药物维持生活参与的作用来促进依从性。
  • 创造支持性环境鼓励患者表达顾虑,以改善治疗满意度、依从性和健康结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Nonadherence to disease-modifying antirheumatic drugs (DMARDS) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) results in increased disease activity and symptoms and poorer quality of life. We aimed to describe patients' attitudes and experiences of DMARDs in RA and SpA to inform strategies to improve medication adherence. METHODS: Databases (MEDLINE, Embase, PsycINFO, and CINAHL) were searched to January 2016. Thematic synthesis was used to analyze the findings. RESULTS: From 56 studies involving 1,383 adult patients (RA [n = 1,149], SpA [n = 191], not specified [n = 43]), we identified 6 themes (with subthemes): intensifying disease identity (severity of sudden pharmacotherapy, signifying deteriorating health, daunting lifelong therapy), distressing uncertainties and consequences (poisoning the body, doubting efficacy, conflicting and confusing advice, prognostic uncertainty with changing treatment regimens), powerful social influences (swayed by others' experiences, partnering with physicians, maintaining roles, confidence in comprehensive and ongoing care, valuing peer support), privilege and right of access to biologic agents (expensive medications must be better, right to receive a biologic agent, fearing dispossession), maintaining control (complete ownership of decision, taking extreme risks, minimizing lifestyle intrusion), and negotiating treatment expectations (miraculous recovery, mediocre benefit, reaching the end of the line). CONCLUSION: Patients perceive DMARDs as strong medications with alarming side effects that intensify their disease identity. Trust and confidence in medical care, positive experiences with DMARDS among other patients, and an expectation that medications will help maintain participation in life can motivate patients to use DMARDs. Creating a supportive environment for patients to voice their concerns may improve treatment satisfaction, adherence, and health outcomes.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Kelly A, Tymms K, Tunnicliffe DJ, et al. Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis. Arthritis Care Res (Hoboken). 2018. PMID: 28732151. doi:10.1002/acr.23329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。